Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 2/20 | 0.31 |
| ▸ | DRD4 | P21917 | 2/20 | 0.31 |
| ▸ | DRD3 | P35462 | 2/20 | 0.31 |
| ▸ | DRD1 | P21728 | 1/20 | 0.31 |
| ▸ | DRD5 | P21918 | 1/20 | 0.31 |
| ▸ | CXCR2 | P25025 | 1/20 | 0.30 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL730886 | 0.81 | MAOB (0.34) | — | |
| SCHEMBL742449 | 0.74 | DRD2 (0.34) | DRD2DRD4DRD3CHRM1 | |
| SCHEMBL25365069 | 0.64 | CXCR2 (0.35) | DRD2DRD4DRD3DRD1DRD5 | |
| SCHEMBL12356798 | 0.64 | DRD2 (0.40) | DRD2DRD4DRD3DRD1DRD5 | |
| SCHEMBL576035 | 0.63 | CA2 (0.50) | DRD2DRD4DRD3DRD1DRD5 | |
| SCHEMBL19482466 | 0.63 | SLC6A4 (0.40) | DRD2DRD4DRD3DRD1DRD5 | |
| SCHEMBL2170025 | 0.62 | CXCR2 (0.45) | DRD2DRD4DRD3DRD1DRD5 | |
| SCHEMBL1180955 | 0.61 | DRD2 (0.40) | DRD2DRD4DRD3DRD1DRD5 | |
| SCHEMBL28726740 | 0.61 | CXCR2 (0.44) | DRD2DRD4DRD3DRD1DRD5 | |
| SCHEMBL19486878 | 0.61 | CXCR2 (0.37) | DRD2DRD4DRD3DRD1DRD5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8138176-B2 | Imidazo compounds | NOVARTIS AG (CH) | 2012-03-20 | — | — | US | disclosed |
| US-20110092492-A1 | IMIDAZO COMPOUNDS | HEROLD PETER | 2011-04-21 | — | — | US | disclosed |
| US-7879847-B2 | such as 4-(5,6-Dihydro-8H-imidazo[5,1-c][1,4]oxazin-5-yl)benzonitrile, having aldosterone synthase and/or 11- beta -hydroxylase inhibitory activity, used for the treatment of hypertension and Cushing's Syndrome | NOVARTIS AG (CH) | 2011-02-01 | — | — | US | disclosed |
| EP-2007770-B1 | IMIDAZO COMPOUNDS | NOVARTIS AG (CH) | 2010-09-08 | — | — | EP | disclosed |
| US-20090192144-A1 | Imidazo Compounds | SPEEDEL EXPERIMENTA AG (CH) | 2009-07-30 | — | — | US | disclosed |
| EP-2007770-A1 | IMIDAZO COMPOUNDS | Speedel Experimenta AG (CH) | 2008-12-31 | — | — | EP | disclosed |
| WO-2007116099-A1 | IMIDAZO COMPOUNDS | SPEEDEL EXPERIMENTA AG (CH) | 2007-10-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090192144-A1 | Imidazo Compounds | REN, CYP11B2, CYP11B1 | DRD2 3443/4885DRD4 3311/4885DRD3 2354/4885 |
| US-20110092492-A1 | IMIDAZO COMPOUNDS | REN, CYP11B2, CYP11B1 | DRD2 3142/4885DRD4 3088/4885DRD3 2194/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.